Wealth Alliance Has $1.42 Million Stake in Abbott Laboratories (NYSE:ABT)

Wealth Alliance increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,939 shares of the healthcare product maker’s stock after purchasing an additional 403 shares during the quarter. Wealth Alliance’s holdings in Abbott Laboratories were worth $1,424,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Altshuler Shaham Ltd bought a new stake in Abbott Laboratories during the fourth quarter worth $28,000. Cornerstone Planning Group LLC bought a new position in shares of Abbott Laboratories in the second quarter valued at about $28,000. FWL Investment Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $33,000. True Wealth Design LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $33,000. Finally, Quarry LP raised its position in shares of Abbott Laboratories by 132.9% in the second quarter. Quarry LP now owns 333 shares of the healthcare product maker’s stock valued at $36,000 after purchasing an additional 190 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares in the company, valued at approximately $14,895,094.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares in the company, valued at approximately $14,895,094.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Andrea F. Wainer sold 42,500 shares of Abbott Laboratories stock in a transaction on Monday, January 29th. The shares were sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the completion of the sale, the executive vice president now owns 65,027 shares of the company’s stock, valued at approximately $7,315,537.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,435 shares of company stock worth $6,451,298. 0.47% of the stock is currently owned by insiders.

Abbott Laboratories Trading Up 0.3 %

ABT opened at $109.20 on Wednesday. The company’s 50 day moving average is $114.57 and its 200-day moving average is $107.60. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. The company has a market cap of $189.48 billion, a P/E ratio of 33.50, a PEG ratio of 2.62 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.19. The business had revenue of $10.24 billion during the quarter, compared to analyst estimates of $10.19 billion. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the business earned $1.03 EPS. Equities research analysts predict that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 2.01%. Abbott Laboratories’s payout ratio is 67.48%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ABT shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $128.00 price target on shares of Abbott Laboratories in a research report on Wednesday, February 14th. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, December 21st. Evercore ISI raised their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Citigroup increased their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Raymond James increased their price objective on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $122.14.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.